The human epidermal growth factor receptor 2 (HER2) is overexpressed in approximately 15%–25% of invasive breast cancers, and is associated with a high risk of disease recurrence and reduced survival [1–3]. This evidence concerns the gene ERBB2 and invasive breast carcinoma.